40.36
price up icon0.21%   0.10
after-market 시간 외 거래: 40.90 0.54 +1.34%
loading
전일 마감가:
$40.26
열려 있는:
$40.26
하루 거래량:
4.90M
Relative Volume:
1.37
시가총액:
$17.24B
수익:
$2.31B
순이익/손실:
$1.66B
주가수익비율:
17.57
EPS:
2.297
순현금흐름:
$827.02M
1주 성능:
-0.75%
1개월 성능:
+5.09%
6개월 성능:
+12.57%
1년 성능:
+34.53%
1일 변동 폭
Value
$39.87
$40.49
1주일 범위
Value
$39.87
$41.70
52주 변동 폭
Value
$29.66
$41.70

로열티 파마 Stock (RPRX) Company Profile

Name
명칭
Royalty Pharma Plc
Name
전화
(212) 883-0200
Name
주소
110 EAST 59TH STREET, NEW YORK, NY
Name
직원
99
Name
트위터
Name
다음 수익 날짜
2025-02-11
Name
최신 SEC 제출 서류
Name
RPRX's Discussions on Twitter

RPRX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
RPRX
Royalty Pharma Plc
40.36 17.20B 2.31B 1.66B 827.02M 2.297
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
454.67 116.86B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
758.91 80.72B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ARGX
Argen X Se Adr
810.51 49.26B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
369.96 49.00B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ONC
Beone Medicines Ltd Adr
351.06 36.96B 4.98B 69.59M 525.67M 0.5197

로열티 파마 Stock (RPRX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-09-30 개시 Goldman Buy
2025-05-16 개시 Morgan Stanley Overweight
2024-06-03 다운그레이드 UBS Buy → Neutral
2022-06-14 재개 UBS Buy
2022-05-13 개시 Scotiabank Sector Outperform
2022-04-27 개시 Goldman Buy
2022-04-14 업그레이드 JP Morgan Neutral → Overweight
2022-04-06 재개 Morgan Stanley Overweight
2021-10-29 업그레이드 Citigroup Neutral → Buy
2021-07-30 개시 Tigress Financial Buy
2020-11-09 업그레이드 UBS Neutral → Buy
2020-07-14 개시 Evercore ISI In-line
2020-07-13 개시 BofA Securities Buy
2020-07-13 개시 Citigroup Neutral
2020-07-13 개시 Cowen Outperform
2020-07-13 개시 Goldman Neutral
2020-07-13 개시 JP Morgan Neutral
2020-07-13 개시 Morgan Stanley Equal-Weight
2020-07-13 개시 SunTrust Buy
2020-07-13 개시 UBS Neutral
모두보기

로열티 파마 주식(RPRX)의 최신 뉴스

pulisher
12:15 PM

Will Royalty Pharma plc stock remain a Wall Street favoriteNew Guidance & Safe Entry Trade Signal Reports - moha.gov.vn

12:15 PM
pulisher
04:26 AM

Terrance Coyne Sells 69,582 Shares of Royalty Pharma (NASDAQ:RPRX) Stock - MarketBeat

04:26 AM
pulisher
04:21 AM

Royalty pharma reports record year for royalty funding market By Investing.com - Investing.com Nigeria

04:21 AM
pulisher
04:02 AM

Royalty Pharma promises $500M to Teva for advancing vitiligo treatment - MSN

04:02 AM
pulisher
Jan 12, 2026

TEVA secures $500 million funding from Royalty Pharma for vitiligo drug - StreetInsider

Jan 12, 2026
pulisher
Jan 12, 2026

Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug - Benzinga

Jan 12, 2026
pulisher
Jan 12, 2026

TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug - TradingView — Track All Markets

Jan 12, 2026
pulisher
Jan 12, 2026

Royalty pharma reports record year for royalty funding market - Investing.com

Jan 12, 2026
pulisher
Jan 12, 2026

Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference - The Manila Times

Jan 12, 2026
pulisher
Jan 12, 2026

Royalty Pharma reports $4.7 billion in transactions for 2025 - StreetInsider

Jan 12, 2026
pulisher
Jan 12, 2026

Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.235 - Yahoo Finance

Jan 12, 2026
pulisher
Jan 12, 2026

Royalty Pharma and Teva’s $500 million IL-15 deal boosts AnaptysBio stock - Investing.com Nigeria

Jan 12, 2026
pulisher
Jan 12, 2026

Royalty Pharma provides up to $500 million for TEVA vitiligo drug - StreetInsider

Jan 12, 2026
pulisher
Jan 12, 2026

Royalty Pharma And Teva Broaden Collaboration To Advance Potential Vitiligo Treatment - Nasdaq

Jan 12, 2026
pulisher
Jan 11, 2026

Royalty Pharma and Teva Enter $500 Million Funding Agreement for TEV-408 Development - Intellectia AI

Jan 11, 2026
pulisher
Jan 11, 2026

Royalty Pharma And Teva Announce $500 Mln Funding Agreement For TEV-408 Development - Nasdaq

Jan 11, 2026
pulisher
Jan 11, 2026

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation - GlobeNewswire Inc.

Jan 11, 2026
pulisher
Jan 11, 2026

Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo - The Manila Times

Jan 11, 2026
pulisher
Jan 11, 2026

Teva and Royalty Pharma enter agreement to accelerate development of potential treatment for vitiligo - marketscreener.com

Jan 11, 2026
pulisher
Jan 11, 2026

Drugmakers commit up to $500M to test a potential new vitiligo treatment - Stock Titan

Jan 11, 2026
pulisher
Jan 11, 2026

A $500 million bet on a new vitiligo treatment aims to speed trials - Stock Titan

Jan 11, 2026
pulisher
Jan 11, 2026

Royalty Pharma PLC (NASDAQ:RPRX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Jan 11, 2026
pulisher
Jan 09, 2026

Royalty Pharma PLC (NASDAQ:RPRX) Increases Dividend to $0.24 Per Share - MarketBeat

Jan 09, 2026
pulisher
Jan 09, 2026

Royalty Pharma buys remaining royalty interest in Roche drug Evrysdi - MSN

Jan 09, 2026
pulisher
Jan 09, 2026

Royalty Pharma’s Q3 2025 Earnings Call Highlights - MSN

Jan 09, 2026
pulisher
Jan 09, 2026

Royalty Pharma raises quarterly dividend by 6.8% to $0.235/share - MSN

Jan 09, 2026
pulisher
Jan 09, 2026

Royalty Pharma plc Declares Dividend on Class A Ordinary Share for the First Quarter of 2026, Payable on March 10, 2026 - MarketScreener

Jan 09, 2026
pulisher
Jan 09, 2026

Royalty Pharma increases quarterly dividend by 6.8% to $0.235 - Investing.com India

Jan 09, 2026
pulisher
Jan 09, 2026

Royalty Pharma shares edge higher on acquisition of oncology drug royalties - MSN

Jan 09, 2026
pulisher
Jan 09, 2026

Royalty Pharma Increases Quarterly Dividend to $0.235 a Share From $0.22, Payable March 10 to Holders of Record on Feb. 20. - MarketScreener

Jan 09, 2026
pulisher
Jan 09, 2026

Royalty Pharma Declares Q1 2026 Dividend of $0.235 per Share, Marking 6.8% Increase - Quiver Quantitative

Jan 09, 2026
pulisher
Jan 09, 2026

Royalty Pharma Announces Dividend Increase - The Manila Times

Jan 09, 2026
pulisher
Jan 09, 2026

Royalty Pharma plc (RPRX) Raises Quarterly Dividend 7.3% to $0.235; 2.3% Yield - StreetInsider

Jan 09, 2026
pulisher
Jan 09, 2026

Moran Wealth Management LLC Increases Position in Royalty Pharma PLC $RPRX - MarketBeat

Jan 09, 2026
pulisher
Jan 09, 2026

Is Royalty Pharma plc stock supported by strong cash flowsInflation Watch & Stock Timing and Entry Methods - ulpravda.ru

Jan 09, 2026
pulisher
Jan 08, 2026

Is Royalty Pharma plc stock affected by interest rate hikesJuly 2025 Opening Moves & Growth Oriented Trade Recommendations - ulpravda.ru

Jan 08, 2026
pulisher
Jan 08, 2026

Trade Report: How risky is Royalty Pharma plc (RPD) stock compared to peersPortfolio Value Summary & Free Expert Verified Stock Movement Alerts - ulpravda.ru

Jan 08, 2026
pulisher
Jan 08, 2026

Is Royalty Pharma plc stock ready for breakoutJuly 2025 Technicals & Short-Term Swing Trade Alerts - ulpravda.ru

Jan 08, 2026
pulisher
Jan 08, 2026

170,604 Shares in Royalty Pharma PLC $RPRX Bought by Hosking Partners LLP - MarketBeat

Jan 08, 2026
pulisher
Jan 08, 2026

Royalty Pharma PLC $RPRX Shares Bought by Robeco Institutional Asset Management B.V. - MarketBeat

Jan 08, 2026
pulisher
Jan 08, 2026

Royalty Pharma stock hits 52-week high at $41.26 By Investing.com - Investing.com Nigeria

Jan 08, 2026
pulisher
Jan 07, 2026

Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Royalty Pharma (NASDAQ:RPRX) - Barchart.com

Jan 07, 2026
pulisher
Jan 07, 2026

Royalty Pharma stock hits 52-week high at $41.26 - Investing.com India

Jan 07, 2026
pulisher
Jan 07, 2026

Royalty Pharma (NASDAQ:RPRX) Sets New 1-Year HighHere's Why - MarketBeat

Jan 07, 2026
pulisher
Jan 07, 2026

United StatesGoodwin Guides Royalty Pharma On Acquisition Of Remaining Royalty Interest In Roche’s Evrysdi For $240 Million And Potential Milestones - Mondaq

Jan 07, 2026
pulisher
Jan 07, 2026

Royalty Pharma plc (NASDAQ:RPRX) Nasdaq Index Life Sciences Partner - Kalkine Media

Jan 07, 2026
pulisher
Jan 05, 2026

Generali Asset Management SPA SGR Grows Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat

Jan 05, 2026
pulisher
Jan 04, 2026

Financiere des Professionnels Fonds d investissement inc. Invests $933,000 in Royalty Pharma PLC $RPRX - MarketBeat

Jan 04, 2026
pulisher
Jan 04, 2026

Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones - citybiz

Jan 04, 2026
pulisher
Jan 02, 2026

Why (RPRX) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Jan 02, 2026
pulisher
Dec 31, 2025

What's Going On With Royalty Pharma Stock Wednesday?Royalty Pharma (NASDAQ:RPRX) - Benzinga

Dec 31, 2025

로열티 파마 (RPRX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

로열티 파마 주식 (RPRX) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Coyne Terrance P.
EVP & CFO
Jan 02 '26
Sale
38.42
69,582
2,673,041
39,760
Urist Marshall
EVP, Research & Investments
Jan 02 '26
Sale
38.48
20,000
769,650
80,000
$103.43
price down icon 2.74%
$33.87
price down icon 0.31%
$119.95
price up icon 2.39%
$107.19
price up icon 4.90%
$163.72
price down icon 2.44%
biotechnology ONC
$351.06
price up icon 5.17%
자본화:     |  볼륨(24시간):